Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT07614360 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07614360
- Sponsor
- GlaxoSmithKline
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-03
- Primary completion
- 2029-02-28
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.